Modified β-lactamases and uses thereof

US7323303; US7323303 B2; US7323303B2; US7,323,303; US7,323,303 B2; 7323303; Application No. 10/401,867Inventor name used in this publication: Thomas Yun-Chung LeungInventor name used in this publication: Pak-Ho ChanUSVersion of Recor

Site-directed pegylation of arginases and use thereof as anti-cancer and anti-viral agents

Inventor name used in this publication: 梁润松Inventor name used in this publication: 劳伟雄Title in Traditional Chinese: 精氨酸酶的定向位點聚乙二醇化及其作為抗癌和抗病毒試劑的用途China2014-2015 > Other Outputs > Patents grantedVersion of Recor

Site-directed pegylation of arginases and the use thereof as anti-cancer and anti-viral agents

US8507245; US8507245 B2; US8507245B2; US8,507,245; US 8,507,245 B2; 8507245; Appl. No. 12/732,188Inventor name used in this publication: Yun Chung LeungInventor name used in this publication: Wai-hung LoUSVersion of Recor

Modified beta-lactamases and uses thereof

Inventor name used in this publication: 黄国贤, Wong KwokyinInventor name used in this publication: 托马斯·润松·梁, Leung Thomas Y.Inventor name used in this publication: 陈百豪, Chan PakhoTitle in Traditional Chinese: 修飾的β-內酰胺酶及其應用ChinaVersion of Recor

Method for production of alpha-amylase in recombinant Bacillus

Disclosed is a novel recombinant Bacillus bacterial strain constructed by genetic engineering which has high productivity of aipha-amylase. The Bacillus strain comprises an alpha-amylase gene inserted in the Bacillus chromosome under transcriptional control of a phage promoter. An efficient process for the rapid production of large amounts of alpha-amylase is also disclosed.Department of Applied Biology and Chemical TechnologyUS7550281; US7550281 B2; US7550281B2; US7,550,281; US 7,550,281 B2; 7550281; Application No. 10/212,806Inventor name used in this publication: Yun Chung LeungInventor name used in this publication: Wai Hung LoU

Method and system for detection of chloramphenicol

US8329425; US8329425 B2; US8329425B2; US8,329,425; US 8,329,425 B2; 8329425; Appl. No. 13/036,021Inventor name used in this publication: Yun Chung LeungUSVersion of Recor

Anticancer dirhodium(ii,ii) carboxylates as potent inhibitors of ubiquitin-proteasome system

Dirhodium(ii,ii) carboxylates are documented to exhibit both in vitro and in vivo anticancer properties. In literatures, DNA is a proposed molecular target of anticancer active dirhodium(ii,ii) compounds. Herein, we provide compelling evidences that for the dirhodium(ii,ii) carboxylates examined in this work (Rh 2L 4, where L = μ 2-OOCMe RhA, μ 2-OOCnPr RhB, μ 2-OOCiBu RhIsoVal, μ 2-OOCiPr RhIsoButyl, μ 2-OOCC 2H 4COPh RhPCOPh or μ 2-OOCC 3H 6COPh RhBCOPh), a prominent mechanism of action is the inhibition of ubiquitin-proteasome system (UPS). Using an unbiased connectivity map analysis, the changes in global gene expression upon treatment of cells with dirhodium(ii,ii) acetate and butyrate are similar to that of proteasome inhibitors. Cellular studies revealed that dirhodium(ii,ii) butyrate at submicromolar concentrations exerts a strong inhibition of UPS, attributable to impairment of proteasomal proteolysis and deubiquitinating enzyme activities. The UPS inhibitory potencies of the dirhodium(ii,ii) carboxylates also exhibit strong correlation with the cytotoxicities. Of note, the dirhodium(ii,ii) carboxylates inhibit UPS at concentrations that were at least 10-fold lower than that required for eliciting DNA damage as determined by comet assay. While cisplatin, oxaliplatin and carboplatin readily induce significant double strand break as indicated by γ-H2AX induction, the dirhodium(ii,ii) carboxylates do not. Our findings revealed that the dirhodium(ii,ii) carboxylates exhibit potent UPS inhibitory property which is linked to their cytotoxic actions. © 2012 The Royal Society of Chemistry.link_to_subscribed_fulltex